Joint bone spine | 2021
Inflammation-targeted therapies and Cancer.
Abstract
OBJECTIVE\nto review and analyze the current knowledge on the risk of malignancy associated with inflammation-targeted therapies in rheumatic diseases.\n\n\nMETHODS\nWe performed a non-systematic literature review on PubMEd MEDLINE by screening randomized controlled trials, meta-analyses, reviews, and observational studies focusing on malignancies and inflammation-targeted therapies including TNF inhibitors, other biologics and JAK inhibitors in rheumatic diseases.\n\n\nRESULTS\nData from literature are reassuring regarding the overall risk of incident and recurrent cancer with TNF inhibitors. The risk of lymphoma is more difficult to analyze and data are controversial, however in most of the studies this risk does not seem to be significanlty increased. By contrast, there is probably an increased risk of non-melanoma skin cancer associated with TNF inhibitors, as with other immunosuppressants. There is no signal for an increased risk of malignancies with other biological DMARDs, but additional data are needed. A recent post-marketing surveillance study found out an increased risk of malignancies for tofacitinib compared with TNFi; additional data are therefore urgently needed to confirm or not these results.\n\n\nCONCLUSION\nData are presently reassuring regarding the overall risk of cancer, whatever the inflammation-targeted treatment. However, additional data are needed for non-TNF biologics and JAK-inhibitors.